Combination of an anti-PD-1 antibody and radiotherapy has shown preclinical success in vivo [53], leading to the phase III CheckMate 143 trial of nivolumab (NCT02017717) comparing it to the approved VEGF-A inhibitor bevacizumab in recurrent GBM. This evidence concerns the gene VEGFA and glioblastoma.